Pulse Biosciences (PLSE) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Pulse Biosciences (PLSE) do?
Pulse Biosciences Inc (PLSE) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Develops medical devices that use nanosecond electrical pulses to clear targeted cellular tissue. Sells consoles and disposable treatment tips to specialty medical clinics. Uses nanosecond electrical pulses to clear diseased cells while sparing surrounding non-cellular tissue structures. It is worth $3.27B on the market and sold $1.49M over the last year.
- Market cap
- $3.27B
- P/E ratio
- None (reported a loss)
- Annual sales
- $1.49M
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 17, 2026
Brands and businesses behind PLSE
- CellFX: Delivers pulsed electric fields to clear soft tissue lesions, generating revenue from console placements and single-use procedural tips.
PLSE’s flags, in plain English
Each flag is a number from Pulse Biosciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Stupid Cash
Can pay this year's bills 14.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 3% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Insiders Hold
Insiders own 69.7% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -5603.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about PLSE
How big is Pulse Biosciences?
Pulse Biosciences’ market cap is $3.27B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.49M: what customers paid the company over the last year, before any costs.
What is PLSE’s P/E ratio?
PLSE has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with PLSE?
The business generates very little commercial revenue and runs at a substantial ongoing net loss while funding clinical trials. That is one risk on Pulse Biosciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Pulse Biosciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PLSE’s filings on SEC.gov. The Margin Monkey is research, not advice.
